Details of the Drug

General Information of Drug (ID: DMSEPK8)

Drug Name

Brivaracetam

Synonyms

Rikelta; UCB-34714; Brivaracetam (USAN/INN)

Indication

Disease Entry	ICD 11	Status	REF
Complex partial seizure	8A68.0	Approved	[1]
Epilepsy	8A60-8A68	Phase 3	[2]
Pain	MG30-MG3Z	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

212.29

Logarithm of the Partition Coefficient (xlogp)

1

Rotatable Bond Count (rotbonds)

5

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

2

ADMET Property

Bioavailability: The bioavailability of drug is 100% [3]
Clearance: The clearance of drug is 0.7-1.07 mL/min/kg [4]
Elimination: More than 95% of excreted in urine with less than 10% of the parent compound unchanged, and less than 1% excreted in feces []
Half-life: The concentration or amount of drug in body reduced by one-half in 7 - 8 hours [3]
Metabolism: The drug is metabolized via the hydrolysis of the acetamide moeity to form a carboxylic acid metabolite [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.825% [6]
Vd: The volume of distribution (Vd) of drug is 0.5 L/kg []

Chemical Identifiers

Formula: C11H20N2O2
IUPAC Name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
Canonical SMILES: CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
InChI: InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
InChIKey: MSYKRHVOOPPJKU-BDAKNGLRSA-N

Cross-matching ID

PubChem CID: 9837243
ChEBI ID: CHEBI:133013
CAS Number: 357336-20-0
DrugBank ID: DB05541
TTD ID: D0CT4D
INTEDE ID: DR0230
ACDINA ID: D00078

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Synaptic vesicle glycoprotein 2A (SV2A)	TTT3P91	SV2A_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[9]
Cytochrome P450 2B6 (CYP2B6)_{Main DME}	DEPKLMQ	CP2B6_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Brivaracetam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Brivaracetam when combined with Levomilnacipran.	Chronic pain [MG30]	[10]
Levonorgestrel	DM1DP7T	Minor	Increased metabolism of Brivaracetam caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[11]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Brivaracetam when combined with Vilazodone.	Depression [6A70-6A7Z]	[10]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Brivaracetam when combined with Vortioxetine.	Depression [6A70-6A7Z]	[10]
Desvenlafaxine	DMHD4PE	Moderate	Antagonize the effect of Brivaracetam when combined with Desvenlafaxine.	Depression [6A70-6A7Z]	[10]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Brivaracetam and Esketamine.	Depression [6A70-6A7Z]	[12]
Oestradiol valerate and dienogest	DMZK0FQ	Minor	Increased metabolism of Brivaracetam caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme.	Endometriosis [GA10]	[13]
Etravirine	DMGV8QU	Minor	Decreased metabolism of Brivaracetam caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Brivaracetam and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[14]
ABIRATERONE	DM8V75C	Minor	Decreased metabolism of Brivaracetam caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[11]
Armodafinil	DMGB035	Minor	Decreased metabolism of Brivaracetam caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[11]
-----------


⏷ Show the Full List of 11 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Brivaracetam 75 mg tablet	75 mg	Oral Tablet	Oral
Brivaracetam 100 mg tablet	100 mg	Oral Tablet	Oral
Brivaracetam 25 mg tablet	25 mg	Oral Tablet	Oral
Brivaracetam 50 mg tablet	50 mg	Oral Tablet	Oral
Brivaracetam 10 mg tablet	10 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2	New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
3	The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008 Jul;66(1):71-5. doi: 10.1111/j.1365-2125.2008.03158.x. Epub 2008 Mar 13.
4	Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, Stockis A: The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007 Jun;63(6):680-8. Epub 2007 Jan 12.
5	Struthers RS, Nicholls AJ, Grundy J, Chen T, Jimenez R, Yen SS, Bozigian HP: Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009 Feb;94(2):545-51. doi: 10.1210/jc.2008-1695. Epub 2008 Nov 25.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39.
8	Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72.
9	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
10	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	Cerner Multum, Inc. "Australian Product Information.".
13	Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
14	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.